| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
We developed a novel microfluidic platform to automatically barcode genomic DNA from individual cancer cells. Using this approach, we sequenced acute myeloid leukemia (AML) tumors targeting up to 62 loci relevant for the disease from thousands of cells. We predict that our platform will enable analysis of heterogeneity in AML and improve stratification and therapy selection.
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Longitudinal
- Total number of consented subjects: 1
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
The samples used in this study were selected based on AML diagnosis and the presence of tumor markers identified in bulk sequencing
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Targeted Genome Panel Mission Bio Tapestri N/A N/A Whole Genome Sequencing Illumina MiSeq N/A N/A - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Leukemia, Myeloid, Acute
- Links to Related Genes
- Authorized Data Access Requests
-
See research articles citing use of the data from this study
- Study Attribution
-
-
Co-first authors
- Maurizio Pellegrino, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Adam Sciambi, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Sebastian Treusch, PhD. Mission Bio, Inc., San Francisco, CA, USA.
-
Authors
- Robert Durruthy-Durruthy, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Kaustubh Gokhale, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Jose Jacob. Mission Bio, Inc., San Francisco, CA, USA.
- Tina X. Chen. Mission Bio, Inc., San Francisco, CA, USA.
- William Oldham. Mission Bio, Inc., San Francisco, CA, USA.
- Jennifer Geis, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Jairo Matthews. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Hagop Kantarjian, MD. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- P. Andrew Futreal, PhD. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Keyur Patel, MD, PhD. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Keith W. Jones, PhD. Mission Bio, Inc., San Francisco, CA, USA.
-
Principal Investigators
- Dennis J. Eastburn, PhD. Mission Bio, Inc., San Francisco, CA, USA.
- Koichi Takahashi, MD. Department of Leukemia and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
-
Funding Sources
- R44 HG009465. National Institutes of Health, Bethesda, MD, USA.
- Khalifa Scholar for Physician Scientist award. Department of Leukemia and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
-
Co-first authors